<DOC>
	<DOCNO>NCT00031616</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I/II trial study effectiveness NB1011 treat patient metastatic recurrent colorectal cancer respond previous treatment .</brief_summary>
	<brief_title>NB1011 Treating Patients With Metastatic Recurrent Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose NB1011 patient fluoropyrimidine-resistant metastatic recurrent colorectal cancer . - Determine safety toxic effect drug patient . - Determine pharmacokinetics drug patient . - Determine efficacy drug patient . OUTLINE : This phase I dose-escalation study follow phase II study . - Phase I : Patients receive NB1011 IV 1 hour day 1-5 . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos NB1011 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience dose-limiting toxicity . - Phase II : Additional patient receive NB1011 MTD phase I . Patients follow day 30 5 month . PROJECTED ACCRUAL : A maximum 25 patient accrued phase I portion study . A total 15-25 patient accrue phase II portion study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Phosphoramidic acid</mesh_term>
	<mesh_term>Brivudine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic recurrent colorectal adenocarcinoma progress within 6 month fluoropyrimidinebased therapy Prior treatment irinotecan without fluorouracil Evaluable measurable disease Unidimensionally measurable disease allow provided CEA least 2 time upper limit normal No meningeal CNS metastases carcinomatous meningitis PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : At least 3 month Hematopoietic : WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 1.5 mg/dL ( regardless liver metastasis ) AST ALT le 1.5 time upper limit normal ( ULN ) ( 3 time ULN liver metastasis present ) PT INR normal PTT normal Renal : Creatinine le 1.5 mg/dL OR Creatinine clearance great 50 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No known hypersensitivity NB1011 excipient vehicle formulation No active uncontrolled serious bacterial , viral , fungal , parasitic infection No prior concurrent alcohol abuse dependency No malignancy within past 2 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix No concurrent medical psychological condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Recovered prior anticancer chemotherapy No concurrent fluoropyrimidinebased thymidylate synthase inhibitor agent Endocrine therapy : Not specify Radiotherapy : Recovered prior anticancer radiotherapy No concurrent radiotherapy except palliative radiotherapy ( control fracture pain ) provide index lesion involve Surgery : Recovered prior anticancer surgery Other : At least 30 day since prior investigational agent No concurrent anticancer therapy No concurrent disulfiram</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>